Livzon Pharmaceutical Group Inc. (SHE:000513)
China
· Delayed Price · Currency is CNY 32.83
+0.16 (0.49%)
Apr 29, 2026, 3:04 PM CST
SHE:000513 Revenue
Livzon Pharmaceutical Group had revenue of 2.87B CNY in the quarter ending March 31, 2026, a decrease of -9.73%. This brings the company's revenue in the last twelve months to 11.71B, down -0.33% year-over-year. In the year 2025, Livzon Pharmaceutical Group had annual revenue of 12.02B with 1.76% growth.
Revenue (ttm)
11.71B
Revenue Growth
-0.33%
P/S Ratio
2.28
Revenue / Employee
1.32M
Employees
8,878
Market Cap
26.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.02B | 208.01M | 1.76% |
| Dec 31, 2024 | 11.81B | -617.70M | -4.97% |
| Dec 31, 2023 | 12.43B | -199.54M | -1.58% |
| Dec 31, 2022 | 12.63B | 565.72M | 4.69% |
| Jan 1, 2022 | 12.06B | 1.54B | 14.67% |
| Jan 1, 2021 | Pro | Pro | Pro |
| Jan 1, 2020 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Jan 1, 2018 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tianjin Pharmaceutical Da Ren Tang Group Corporation | 4.92B |
| Dizal (Jiangsu) Pharmaceutical | 801.14M |
| Shijiazhuang Yiling Pharmaceutical | 6.01B |
| Hubei Jumpcan Pharmaceutical | 5.90B |
| Kangmei Pharmaceutical | 5.25B |
| Zhejiang Huahai Pharmaceutical | 8.71B |
| Chengdu Kanghong Pharmaceutical Group | 4.43B |
| Humanwell Healthcare (Group) | 23.96B |